Diaz N M, Mazoujian G, Wick M R
Department of Pathology, Barnes Hospital, St Louis, Mo.
Arch Pathol Lab Med. 1991 Dec;115(12):1203-7.
Epidemiologic features of well-differentiated thyroid tumors and experimental evidence suggest that female sex hormones may exert effects on this gland and its neoplasms. This possibility was addressed by investigating the expression of estrogen-receptor protein in 80 thyroid neoplasms. Patients with papillary carcinomas, follicular carcinomas, and follicular adenomas were selected from each of the following groups: (1) postpubertal-premenopausal women (who are associated with the most favorable prognosis and greatest incidence of these neoplasms); (2) postmenopausal women; and (3) men of various ages. Sections from formalin-fixed paraffin-embedded tumors were stained with antiestrophilin antibody (clone H222) and the avidin-biotin-peroxidase complex method. In addition, other markers were included to distinguish thyroidal from other estrogen-receptor protein-reactive neoplasms; an anticytokeratin mixture, antithyroglobulin, and anti-gross cystic disease fluid protein-15 were applied in all cases. The expression of estrogen-receptor protein was detected in eight of 10, six of 10, and nine of 10 papillary carcinomas; four of eight, two of seven, and one of five follicular carcinomas; and none of 10, none of 10, and two of 10 follicular adenomas, in groups 1, 2, and 3, respectively. Nuclear staining was regional or multifocal in distribution. Cytokeratin and thyroglobulin were detected in all tumors. In contrast, none displayed anti-gross cystic disease fluid protein-15 immunoreactivity. These results indicate that the estrogen receptor may be detected immunohistochemically in thyroid neoplasms. However, no differences that could account for possible estrogen-related epidemiologic and prognostic variation in such tumors could be ascertained. Other discriminating immunostains, primarily including anti-gross cystic disease fluid protein-15 and thyroglobulin, are effective in distinguishing between thyroidal and extrathyroidal tumors that may express estrogen-receptor protein.
高分化甲状腺肿瘤的流行病学特征及实验证据表明，女性性激素可能对该腺体及其肿瘤产生影响。通过研究80例甲状腺肿瘤中雌激素受体蛋白的表达情况来探讨这种可能性。分别从以下几组中选取乳头状癌、滤泡状癌和滤泡性腺瘤患者：（1）青春期后绝经前女性（这类肿瘤预后最佳且发病率最高）；（2）绝经后女性；（3）不同年龄段男性。用抗雌激素受体蛋白抗体（克隆号H222）及抗生物素蛋白-生物素-过氧化物酶复合物法对福尔马林固定石蜡包埋肿瘤的切片进行染色。此外，还采用其他标志物来区分甲状腺肿瘤与其他雌激素受体蛋白反应性肿瘤；所有病例均应用抗细胞角蛋白混合物、抗甲状腺球蛋白和抗巨大囊肿病液体蛋白-15。在第1组、第2组和第3组中，分别有10例乳头状癌中的8例、10例中的6例和10例中的9例检测到雌激素受体蛋白表达；8例滤泡状癌中的4例、7例中的2例和5例中的1例；10例滤泡性腺瘤中的0例、10例中的0例和10例中的2例。核染色呈区域性或多灶性分布。所有肿瘤均检测到细胞角蛋白和甲状腺球蛋白。相反，无一例显示抗巨大囊肿病液体蛋白-15免疫反应性。这些结果表明，雌激素受体可在甲状腺肿瘤中通过免疫组织化学方法检测到。然而，未能确定能解释此类肿瘤中可能存在的与雌激素相关的流行病学和预后差异的差异。其他鉴别性免疫染色，主要包括抗巨大囊肿病液体蛋白-15和甲状腺球蛋白，可有效区分可能表达雌激素受体蛋白的甲状腺肿瘤和甲状腺外肿瘤。
